Shares of Elevance Health Inc. (NYSE:ELV) dropped to a new 52-week low of $275.60, reflecting a turbulent year for the healthcare insurer as it grapples with operational challenges and macroeconomic pressures.
Despite a market cap of $62.8 billion and a price-to-earnings ratio of 11.85 suggesting the stock may be undervalued relative to its estimated fair value, investor sentiment has turned cautious. The stock has fallen nearly 45% over the past year, signaling deep concerns over the company’s near-term outlook.
Still, Elevance continues to exhibit solid fundamentals. It posted 10.21% year-over-year revenue growth and has maintained a 14-year streak of consecutive dividend increases—factors that may appeal to value-focused investors even as the broader healthcare sector faces mounting pressures.
Recent second-quarter earnings were closely watched by analysts, with adjusted earnings per share coming in at $8.84, matching consensus expectations. Revenue reached $49.8 billion, topping analyst forecasts by roughly 2.8%. However, a medical loss ratio (MLR) of 88.9%, coupled with ongoing strain in Medicaid and Affordable Care Act (ACA) business lines, has clouded the outlook.
Brokerage firms including Bernstein, UBS, and Guggenheim have all cut their price targets on the stock, citing prolonged margin recovery in government-sponsored programs. TD Cowen also reduced its target price but maintained a Buy rating, highlighting resilient performance in non-Medicaid business areas.
Cantor Fitzgerald reiterated an Overweight rating, though it expressed caution about non-recurring tailwinds that contributed to recent earnings strength. Meanwhile, UBS and Guggenheim noted that despite short-term pressures, there is still potential for profit stability and growth in select business segments.
As investors weigh the stock’s sharp downturn against its long-term fundamentals, Elevance’s future performance will depend heavily on its ability to manage healthcare cost inflation and navigate regulatory complexity in public health programs.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.